Firm intentionConsumer & Retail6 August 2026

Mentholatum Australasia Pty Ltd to acquire Pain Away

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Mentholatum Australasia Pty Ltd
Target
Pain Away
Deal value
Not disclosed
Announced
6 August 2026
Status
Firm intention
Sector
Consumer & Retail
Country
Australia
Consideration
cash, earn-out
What we know

Mentholatum Australasia Pty Ltd has agreed to acquire Pain Away, a consumer and retail business based in Australia, in a strategic acquisition. The transaction, announced on 6 August 2026, carries a headline offer value of 19.8 million. The consideration structure comprises both cash and earn-out components, reflecting a mixed payment approach typical for such strategic purchases. This deal represents a significant move for the Australian buyer, which is expanding its footprint within the domestic consumer sector through the acquisition of Pain Away. The target operates within the broader consumer and retail industry, positioning it as an attractive asset for strategic growth. Both entities are located in Australia, facilitating a domestic transaction that avoids cross-border complexities. The deal structure suggests a focus on future performance alignment through the earn-out element, while the cash portion provides immediate liquidity. This acquisition highlights the ongoing consolidation and strategic expansion activities within the Australian consumer market.

The transaction remains in the firm intention stage, indicating that definitive agreements have likely been signed but closing conditions are yet to be satisfied. As the deal has not yet completed, the final timeline for integration and operational handover remains pending. Regulatory approvals and other customary closing conditions will need to be met before the acquisition can be finalised. The parties are expected to proceed with the necessary steps to complete the transfer of ownership. Stakeholders will be monitoring the progress closely as the deal moves towards completion. The outcome of this acquisition will likely impact the competitive landscape within the Australian consumer and retail sector. Further details regarding the specific terms of the earn-out and the exact closing date will be disclosed as they become available. The focus now shifts to satisfying the remaining conditions precedent to close the transaction.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update
  1. Firm intention

    Sale of Pain Away for up to A$21.3 million

    Disclaimer*   ASX/AIM Announcement                                                                                                                                 6 August 2026 Sale of Pain Away for up to A$21.3 million Wellnex Life Limited (ASX/AIM: WNX) (" Wellnex Life " or the " Company ") is pleased to announce it has entered into a formal binding agreement (" Agreement ") to sell

    LSE RNS

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Consumer & Retail M&A activity tracked by Exit Mode.

Buyer history

Mentholatum Australasia Pty Ltd

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive